Literature DB >> 6384945

Ceftazidime versus tobramycin/ticarcillin in treating hospital acquired pneumonia and bacteremia.

R P Rapp, B Young, T S Foster, P A Tibbs, W O'Neal.   

Abstract

Thirty-five patients in a neurosurgical intensive care unit who had nosocomial pneumonia and bacteremia were randomly assigned to receive either ceftazidime (Cef) or the combination of ticarcillin and pharmacokinetically adjusted doses of tobramycin (T/T). Fifteen of 17 patients (88%) who received Cef were cured or improved compared to 15 of 18 (83%) who received T/T. The original pathogen was eradicated from the respiratory secretion in 10 of 15 patients receiving Cef compared to only 6 of 18 patients receiving T/T (p = 0.12). All patients in both treatment groups who had positive blood cultures cleared the organism from the bloodstream. No cases of drug toxicity, including renal toxicity, were seen in either group. Cef used as a single agent in nosocomial pneumonias and bacteremias performed at least as well as T/T.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6384945     DOI: 10.1002/j.1875-9114.1984.tb03360.x

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  10 in total

1.  Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria.

Authors:  Elpis Giantsou; Nikolaos Liratzopoulos; Eleni Efraimidou; Maria Panopoulou; Eleonora Alepopoulou; Sofia Kartali-Ktenidou; George I Minopoulos; Spyros Zakynthinos; Konstantinos I Manolas
Journal:  Intensive Care Med       Date:  2005-09-07       Impact factor: 17.440

Review 2.  Systemic antibiotic treatment of nosocomial pneumonia.

Authors:  K E Unertl; F P Lenhart; H Forst; K Peter
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 3.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 4.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

Review 5.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.

Authors:  Mical Paul; Ishay Benuri-Silbiger; Karla Soares-Weiser; Leonard Leibovici
Journal:  BMJ       Date:  2004-03-02

6.  Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 7.  Systemic antimicrobial therapy of nosocomial pneumonia: monotherapy versus combination therapy.

Authors:  F M LaForce
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-01       Impact factor: 3.267

Review 8.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

9.  Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

Authors:  Coleman Rotstein; Gerald Evans; Abraham Born; Ronald Grossman; R Bruce Light; Sheldon Magder; Barrie McTaggart; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

Review 10.  Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy.

Authors:  R G Masterton; A Galloway; G French; M Street; J Armstrong; E Brown; J Cleverley; P Dilworth; C Fry; A D Gascoigne; Alan Knox; Dilip Nathwani; Robert Spencer; Mark Wilcox
Journal:  J Antimicrob Chemother       Date:  2008-04-29       Impact factor: 5.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.